Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy

Herda, Lars R.; Trimpert, Christiane; Nauke, Ute; Landsberger, Martin; Hummel, Astrid; Beug, Daniel; Kieback, Arne; Dörr, Marcus; Empen, Klaus; Knebel, Fabian; Ewert, Ralf; Angelow, Aniela; Hoffmann, Wolfgang; Felix, Stephan B.; Staudt, Alexander

doi:10.1016/j.ahj.2010.01.012

Cited by 53 publications

(34 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In order to strictly maintain the criteria of previous reports in the present study, we excluded NYHA class 2 patients, although according to recent trials in Germany, this patient group has also been reported to derive therapeutic benefits from IA. 20 …”

Section: Selection Validitymentioning

confidence: 99%

Complete Elimination of Cardiodepressant IgG3 Autoantibodies by Immunoadsorption in Patients With Severe Heart Failure

Baba

Amaki

Shimada

et al. 2010

Circ J

View full text Add to dashboard Cite

Background: Cardiodepressant IgG3 autoantibodies (CD-Abs) can be targeted by apheresis. Using blinded measurements of CD-Abs before and after immunoadsorption (IA), the cardiac function of patients who did or did not achieve complete CD-Abs elimination was compared. Methods and Results:Autoantibodies were completely removed from 18 patients with heart failure (New York Heart Assocation class 3 or 4, left ventricular ejection fraction (LVEF) <30%) using a selective IgG3 adsorption column. All patients had anti-β1-adrenergic and/or M2-muscarinic autoantibodies before IA, and all LVEF were measured on radionuclide ventriculography. CD-Abs were measured before and after IA, and patient status was blinded until all measurements were collected. Treatment was defined as complete when CD-Abs status changed from positive to negative after IA. Other instances were defined as incomplete. Six-min walk test results and brain natriuretic peptide levels improved significantly after IA (P<0.01). The increase in LVEF 3 months after IA was significantly greater after complete treatment in comparison to the incomplete treatment group (19±8-29±9% vs 18±9-17±8%, P<0.01). Cardiac insufficiency events were also more frequent in the incomplete treatment group. Conclusions:Complete elimination of CD-Abs with apheresis may be related to improved cardiac function in the treatment of heart failure. (Circ J 2010; 74: 1372 - 1378

show abstract

Section: Selection Validitymentioning

confidence: 99%

Complete Elimination of Cardiodepressant IgG3 Autoantibodies by Immunoadsorption in Patients With Severe Heart Failure

Baba

Amaki

Shimada

et al. 2010

Circ J

View full text Add to dashboard Cite

show abstract

“…Disease duration was less than 1 year. In all patients, significant coronary artery disease or heart valve diseases were ruled out by angiography and echocardiography, respectively, as described previously (19). Active infectious diseases, pulmonary diseases, cancer, chronic alcoholism, or heart failure due to known origins were excluded.…”

Section: Methodsmentioning

confidence: 99%

“…Spirometry-Spirometry was used for the quantification of lung performance as described previously (19). Lung function was indexed by forced vital capacity, forced expiratory volume in 1 s (lung), forced expiratory volume in 1 s/forced vital capacity ratio (%), total lung capacity, and residual volume (lung).…”

Section: Methodsmentioning

confidence: 99%

Variants of Toll-like Receptor 4 Predict Cardiac Recovery in Patients with Dilated Cardiomyopathy

Riad

Schwabedissen

Weitmann

et al. 2012

Journal of Biological Chemistry

Self Cite

View full text Add to dashboard Cite

Background:The impact of polymorphisms of TLR4 on left ventricular performance in DCM patients is unknown. Results: Patients carrying TLR4 variants had reduced improvement of left ventricular function and dilation and no increase in NT-pro-BNP level at follow up when compared with wild type genes. Conclusion: TLR4 variants predict cardiac recovery in DCM.Significance: This is the first study to investigate the impact of an innate immune receptor on cardiac recovery in human DCM.

show abstract

“…Small, open, controlled or uncontrolled studies showed that removal of circulating antibodies by unspecific immunoadsorption with subsequent IVIG substitution (IA) results in improvement of cardiac function, better exercise capacity, and a decrease in myocardial inflammation [25,26]. IA has also been shown to be related to alterations of the cellular immune response.…”

Section: Immunoadsorptionmentioning

confidence: 99%

Viral heart disease — treatment

Pawlak¹,

Gil²,

Dörr³

2017

Kardiol Pol

Self Cite

View full text Add to dashboard Cite

Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy

Cited by 53 publications

References 33 publications

Complete Elimination of Cardiodepressant IgG3 Autoantibodies by Immunoadsorption in Patients With Severe Heart Failure

Complete Elimination of Cardiodepressant IgG3 Autoantibodies by Immunoadsorption in Patients With Severe Heart Failure

Variants of Toll-like Receptor 4 Predict Cardiac Recovery in Patients with Dilated Cardiomyopathy

Viral heart disease — treatment

Contact Info

Product

Resources

About